Anlotinib plus Sintilimab
Phase 2Monoclonal antibody
Anlotinib plus Sintilimab is one of 15 small molecule programs targeting Clear Cell Renal Carcinoma. It is currently in Phase 2.
3
Indications
6
Total Trials
3
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Clear Cell Renal Carcinoma
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Xtandi
AstellasApproved
Gleevec
NovartisApproved
Inlyta
PPrism Pharmaceuticals
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Tarceva
OOSI Pharmaceuticals
Approved
Ixempra
RR-Pharm
Approved
Caprelsa
GGenzyme, a Sanofi Company
Approved
Anlotinib plus Sintilimab
SSun Yat-sen University
Phase 2
Sasanlimab
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Soft-tissue Sarcoma1 trial
Endometrial Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anlotinib plus Sintilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SSun Yat-sen University